Funding for lung treatment

Enterprise Therapeutics Ltd, which is developing compounds for respiratory diseases by targeting unwanted mucus in the lungs, has raised £29 million in an oversubscribed Series B financing round co-led by Versant Ventures and the Novartis Venture Fund.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom